<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03653481</url>
  </required_header>
  <id_info>
    <org_study_id>18-015331</org_study_id>
    <nct_id>NCT03653481</nct_id>
  </id_info>
  <brief_title>Treating IBD With Inulin</brief_title>
  <acronym>TII</acronym>
  <official_title>Safety and Feasibility of Oligofructose-Enriched Inulin in Pediatric Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beneo GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see how the prebiotic inulin changes the gut bacteria&#xD;
      (microbiome) of children and young adults with IBD and determine if this dietary intervention&#xD;
      can help reduce disease activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pathogenesis of inflammatory bowel disease (IBD) is thought to be due to a combination of&#xD;
      genetic, environmental and immunological factors. From a clinical stand point, there is great&#xD;
      interest in determining if manipulation of the gut microbiota may be a viable therapeutic&#xD;
      strategy in IBD patients. One such strategy involves the use of prebiotic. Prebiotics are&#xD;
      oligosaccharides that cannot be enzymatically hydrolyzed in the small intestine, however&#xD;
      serve as substrates for fermentation by commensal bacteria in the colon.&#xD;
&#xD;
      Investigators propose to evaluate the modulatory effects of the prebiotic inulin on the&#xD;
      composition and function of the microbiota of children with IBD and determine the efficacy of&#xD;
      this dietary intervention in reducing disease activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alteration of gut microbiota and metabolome</measure>
    <time_frame>8 weeks</time_frame>
    <description>The primary outcome will be assessed based on specific inulin-induced changes in microbiome composition and metabolome with a focus on short-chain fatty acid (SCFA) producers and their metabolites at week 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fecal calprotectin level</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in fecal calprotectin following OI supplementation will be assessed 8 weeks after randomization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Inulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oligofructose-enriched Inulin (OI) administered for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin placebo administered for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oligofructose-enriched Inulin OI</intervention_name>
    <description>Consumed as a powder, 8g/d for children &lt;50kg and 16g/d for children ≥50kg, divided in 2 daily doses.</description>
    <arm_group_label>Inulin</arm_group_label>
    <other_name>Orafti®Synergy1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Consumed as a powder, 8g/d for children &lt;50kg and 16g/d for children ≥50kg, divided in 2 daily doses.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Males or females age 8-21 years.&#xD;
&#xD;
          -  Parental/guardian permission (informed consent) and child assent.&#xD;
&#xD;
          -  Pediatric diagnosis of inflammatory colonic or ileocolonic Crohn's disease (CD),&#xD;
             ulcerative colitis (UC) or inflammatory bowel disease-unclassified (IBDU), as defined&#xD;
             by endoscopy, radiology, and clinical findings.&#xD;
&#xD;
          -  Clinical disease activity index compatible with:&#xD;
&#xD;
               -  For patients with CD:&#xD;
&#xD;
                    -  Pediatric Crohn's Disease Activity Index (PCDAI) ≤15 or short PCDAI (sPCDAI)&#xD;
                       ≤17.5 (if unable to complete full PCDAI) or physician global assessment&#xD;
                       (PGA) compatible with quiescent disease at time of enrollment&#xD;
&#xD;
                    -  No visible blood in bowel movements in the 7 days prior to enrollment&#xD;
&#xD;
                    -  Normal inflammatory laboratory markers (CRP, ESR, Albumin in the case of&#xD;
                       PCDAI)&#xD;
&#xD;
               -  For patients with UC/IBDU:&#xD;
&#xD;
                    -  Pediatric Ulcerative Colitis Activity Index (PUCAI) ≤ 20 or PGA compatible&#xD;
                       with quiescent disease&#xD;
&#xD;
                    -  No visible blood in bowel movements in the 7 days prior to enrollment&#xD;
&#xD;
          -  Fecal calprotectin (FC) ≥ 50 ≤ 500mcg/g or FC outside of this range but within the 20%&#xD;
             margin of error of 500 mcg/g&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Positive culture for an enteropathogen up to a month prior to enrollment or during the&#xD;
             study period.&#xD;
&#xD;
          -  PCDAI &gt;15 or sPCDAI &gt;17.5 for patients with CD or PUCAI &gt;20 for patients with UC or&#xD;
             IBDU&#xD;
&#xD;
          -  Presence of an ostomy or prior colonic resection&#xD;
&#xD;
          -  Short bowel syndrome&#xD;
&#xD;
          -  Isolated perianal disease.&#xD;
&#xD;
          -  Patients requiring escalation of treatment during the intervention or preceding&#xD;
             enrollment, defined by the following: change in dose of azathioprine/methotrexate&#xD;
             during the preceding 12 weeks or 5-amino salicylic acid during the preceding 2 weeks,&#xD;
             change in dosing or interval of anti-TNF therapy, or any other biologic therapy&#xD;
             (ustekinumab, vedolizumab) for the preceding infusion or injection. De-escalation of&#xD;
             therapy (i.e stopping a medication, or spacing the interval of medication or&#xD;
             decreasing the dose of a medication) is acceptable.&#xD;
&#xD;
          -  Use of oral steroids (with the exception of budesonide) within the last 4 weeks of the&#xD;
             screening visit or during the study period.&#xD;
&#xD;
          -  Use of any antibiotics during the preceding 4 weeks or during the study period.&#xD;
&#xD;
          -  Use of commercially available prebiotic preparations during the preceding 3 weeks&#xD;
             prior to starting the study drug or during the study period.&#xD;
&#xD;
          -  Non-inflammatory Crohn's disease (stricturing and/or penetrating disease behavior)&#xD;
&#xD;
          -  Isolated small bowel Crohn's disease&#xD;
&#xD;
          -  Previous ileocecal resection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Breton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Crisci</last_name>
    <phone>267-426-9249</phone>
    <email>TII@chop.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naomi Pressman</last_name>
    <phone>267-426-8413</phone>
    <email>TII@chop.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Crisci</last_name>
      <phone>267-426-9249</phone>
      <email>TII@chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Naomi Pressman</last_name>
      <phone>267-426-8413</phone>
      <email>TII@chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jessica Breton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lindsey Albenberg, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Baldassano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diet</keyword>
  <keyword>inulin</keyword>
  <keyword>prebiotic</keyword>
  <keyword>IBD</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

